Skip to Content
MilliporeSigma
All Photos(1)

Documents

OP40

Sigma-Aldrich

Anti-Pan-Ras (Ab-3) Mouse mAb (RAS 10)

liquid, clone RAS 10, Calbiochem®

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
NACRES:
NA.43

biological source

mouse

Quality Level

antibody form

purified antibody

antibody product type

primary antibodies

clone

RAS 10, monoclonal

form

liquid

contains

≤0.1% sodium azide as preservative

species reactivity

human, mouse, rat

manufacturer/tradename

Calbiochem®

storage condition

do not freeze

isotype

IgG2a

shipped in

wet ice

storage temp.

2-8°C

target post-translational modification

unmodified

Gene Information

human ... KRAS(3845)

General description

Purified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with SP2/0 myeloma cells (see application references). Recognizes the ~21 kDa Ras protein.
Recognizes the ~21 kDa H-, K-, and N-Ras proteins in SW480 and Y1 cells and breast carcinoma tissue.
This Anti-Pan-Ras (Ab-3) Mouse mAb (RAS 10) is validated for use in FC, Frozen Sections, Immunoblotting, IF, IP, Paraffin Sections for the detection of Pan-Ras (Ab-3).

Immunogen

recombinant human p21 Ras

Application


Flow Cytometry (2.5 g/ml)
Frozen Sections (2.5 g/ml)
Immunoblotting (0.1-3 g/ml, chemiluminescent and colorimetric, see application references)
Immunofluorescence (2.5 g/ml, see application references)
Immunoprecipitation (1 g/sample)
Paraffin Sections (2.5 g/ml, saponin pre-treatment required)

Packaging

Please refer to vial label for lot-specific concentration.

Warning

Toxicity: Standard Handling (A)

Analysis Note

Positive Control
SW480 or Y1 cells or breast carcinoma tissue

Other Notes

Rodenhuis, S. et al., 1992. Cancer Res. (Suppl)52, 2665s.
Sidransky, D., et al. 1992. Science256, 102.
Hamer, P.J., et al. 1990. Hybridoma9, 573.
Bos, J.L. 1989. Cancer Res.49, 4682.
Furth, M. E., et al. 1987. Oncogene1, 47.
Kraus, M.H., et al. 1984. Proc. Natl. Acad. Sci. USA81, 5384.
Shimizu, K., et al. 1983. Proc. Natl. Acad. Sci. USA80, 2112.
Taparowsky, E., et al. 1983. Cell34, 581.
Ellis, R.W., et al. 1981. Nature292, 506.
Shih, T.Y., et al. 1980. Nature287, 686.
The level of expression of p21ras is variable in different tissues. For this reason we recommend a concentration step prior to immunoblot analysis to obtain optimal results. Antibody should be titrated for optimal results in individual systems.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

wgk_germany

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

J M English et al.
The Journal of biological chemistry, 274(44), 31588-31592 (1999-10-26)
The activity of the catalytic domain of the orphan MAP kinase ERK5 is increased by Ras but not Raf-1 in cells, which suggests that ERK5 might mediate Raf-independent signaling by Ras. We found that Raf-1 does contribute to Ras activation
J M English et al.
The Journal of biological chemistry, 273(7), 3854-3860 (1998-03-28)
Extracellular signal-regulated protein kinase 5 (ERK5) is a recently discovered orphan mitogen-activated protein kinase for which no substrates or strong activators have been described. Two ERK5 chimeras were created as a novel approach to discover its substrates and upstream regulators.
Alisa Morshneva et al.
Cells, 9(1) (2020-01-08)
The adenoviral early region 1A (E1A) protein has proapoptotic and angiogenic activity, along with its chemosensitizing effect, making it the focus of increased interest in the context of cancer therapy. It was previously shown that E1A-induced chemosensitization to different drugs
Lauren L Fonseca et al.
Translational oncology, 14(1), 100880-100880 (2020-10-20)
Ras mutations are present in only a subset of sporadic human cutaneous squamous cell carcinomas (cSCC) even though Ras is activated in most. This suggests that other mechanisms of Ras activation play a role in the disease. The aberrant expression
Qing-Fen Li et al.
Cell reports, 24(11), 2869-2882 (2018-09-13)
Cerebrovascular malformations (CVMs) affect approximately 3% of the population, risking hemorrhagic stroke, seizures, and neurological deficits. Recently Ras mutations have been identified in a majority of brain arterio-venous malformations. We generated an endothelial-specific, inducible HRASV12 mouse model, which results in

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service